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Summary
 
It has been suggested that Fas ligand–Fas receptor interactions are involved in the regulation of
eosinophil apoptosis and that dysfunctions in this system could contribute to the accumulation
of these cells in allergic and asthmatic diseases. Here, we demonstrate that nitric oxide (NO)
specifically prevents Fas receptor–mediated apoptosis in freshly isolated human eosinophils. In
contrast, rapid acceleration of eosinophil apoptosis by activation of the Fas receptor occurs in
the presence of eosinophil hematopoietins. Analysis of the intracellular mechanisms revealed
that NO disrupts Fas receptor–mediated signaling events at the level of, or proximal to, Jun ki-
nase (JNK), but distal to sphingomyelinase (SMase) activation and ceramide generation. In ad-
dition, activation of SMase occurs downstream of an interleukin 1 converting enzyme–like
(ICE-like) protease(s) that is not blocked by NO. However, NO prevents activation of a pro-
tease that targets lamin B
 
1
 
. These findings suggest a role for an additional NO-sensitive apo-
ptotic signaling pathway that amplifies the proteolytic cascade initialized by activation of the
Fas receptor. Therefore, NO concentrations within allergic inflammatory sites may be impor-
tant in determining whether an eosinophil survives or undergoes apoptosis upon Fas ligand
stimulation.
 
I
 
nhibition of eosinophil apoptosis has been proposed as a
key mechanism for the development of blood and tissue
eosinophilia in diseases such as bronchial asthma and other
allergic disorders (1, 2). The delay of eosinophil death might
be due, at least in part, to overproduction of T cell–derived
cytokines (2–9). Besides cytokines, eosinophil apoptosis also
seems to be regulated by at least one member of the TNF/
nerve growth factor (NGF) receptor superfamily, namely
the Fas receptor (CD95/APO-1) (10–13). Cross-linking of
the Fas receptor is associated with the induction of apopto-
sis in eosinophils from normal individuals. In contrast, blood
and tissue eosinophils derived from eosinophilic donors of-
ten do not undergo cell death after Fas receptor cross-link-
ing, although Fas protein is normally expressed in these
cells, suggesting that receptor activity is regulated as previ-
ously observed in other systems (13). Fas receptor suscepti-
bility does not seem to be regulated by cytokines that pro-
mote eosinophil survival (10, 11).
Patients with bronchial asthma and allergic rhinitis show
an increased level of nitric oxide (NO)
 
1
 
 in exhaled air (14,
 
15). NO originates from the biotransformation of 
 
l
 
-arginine
to 
 
l
 
-citrulline by an enzyme called NO synthase (NOS; 16).
There is evidence that the inducible isoform of NOS
(iNOS) is expressed in the bronchial mucosa of patients
with bronchial asthma, but not of normal control individu-
als (17), suggesting that increased levels of NO may result
from increased NO production by iNOS. Recently, it has
been demonstrated that eosinophils themselves are a source
of NO production in eosinophilic inflammation (18).
The pathophysiological consequences of increased NO
production in allergic diseases are not yet known. How-
ever, it is clear that NO has effects on immune responses.
For example, NO inhibits both the proliferation of Th1s and
their production of IL-2 and IFN-
 
g
 
, as demonstrated in
several infectious disease models (19, 20). In contrast, Th2s are
not affected by NO (21). These data suggest that increased
amounts of NO may contribute to a preferential Th2 re-
sponse in allergic diseases of the respiratory tract (22).
 
1
 
Abbreviations used in this paper:
 
 DAG, 1,2-dioctanoyl-sn-glycerol; db,
dibutyryl; DISC, death-inducing signaling complex; ECL, enhanced
 
chemiluminescence; IBMX, 3-isobutyl-1-methylxanthine; ICE, IL-1
converting enzyme; iNOS, inducible isoform of NOS; JNK, Jun kinase;
LY 83583, 6-anilinoquinoline-5,8-quinone; MAP, mitogen-activated
protein; mRNA, messenger RNA; NMMA, N
 
G
 
-monomethyl-
 
l
 
-argi-
nine; NO, nitric oxide; NOS, NO synthase; PS, phosphatidylserine; sGC,
soluble guanylyl cyclase; SM, sphingomyelin; SMase, sphingomyelinase;
SNAP, 
 
S
 
-nitroso-
 
N
 
-acetylpenicillamine.
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Consequently, we were interested in whether NO may
also play a role in later events of Th2 responses such as in-
hibition of eosinophil apoptosis (1, 2). A possible involve-
ment of NO in defective Fas ligand–Fas receptor interac-
tions was concluded from studies performed in mice where
NO protected liver cells from TNF-induced apoptosis (23).
Since at least one signaling cascade in the induction of cell
death is common to both TNF and Fas receptors (24), we
hypothesized that NO, at least in some cellular systems,
may also counterregulate Fas receptor–mediated apoptosis.
In this study, we demonstrate that NO mediates a func-
tional defect in the Fas receptor signal transduction cascade
in human eosinophils.
 
Materials and Methods
 
Reagents and Antibodies
 
All cell cultures were performed using complete culture medium,
which was RPMI 1640 supplemented with 10% fetal calf serum
(both Life Technologies, Basel, Switzerland). SNAP (
 
S
 
-nitroso-
 
N
 
-acetylpenicillamine), dibutyryl-cGMP, dibutyryl-cAMP, C
 
2
 
-
ceramide, C
 
6
 
-ceramide, C
 
2
 
-dihydroceramide, DAG (1,2-dioc-
tanoyl-sn-glycerol), IBMX (3-isobutyl-1-methylxanthine), LY
83583 (6-anilinoquinoline-5,8-quinone), and GST-fusion protein
of c-Jun (GST-c-Jun, 1–79) were from Biomol (Plymouth Meet-
ing, PA). Azide and hydroxylamine hydrochloride were obtained
from Fluka (Buchs, Switzerland). The IL-1 converting enzyme
(ICE) inhibitor II (
 
N
 
-acetyl-Tyr-Val-Ala-Asp-chloromethylke-
tone; Ac-YVAD-cmk) was obtained from Bachem (Bubendorf,
Switzerland). N
 
G
 
-monomethyl-
 
l
 
-arginine (NMMA) was from
Alexis Corp. (Läufelfingen, Switzerland). The concentrations used
for all these reagents are indicated in the text and figure legends.
Anti-CD16 mAb microbeads were from Miltenyi Biotec (Ber-
gisch-Gladbach, Germany). Unconjugated (clone CH-11, IgM)
and FITC-conjugated (clone UB2, IgG
 
1
 
) anti-CD95 mAb were
from Immunotech (Marseille, France). For functional assays, anti-
Fas mAb (IgM) was used at 1 
 
m
 
g/ml. Anti–Jun kinase (JNK) Ab
(C-17) was from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti–human lamin B
 
1
 
 mAb (clone 101-B7, IgG
 
1
 
) was from
Matritech Inc. (Cambridge, MA). Neutralizing anti–GM-CSF mAb
was purchased from R&D Sys. Inc. (Minneapolis, MN). LPS was
from Sigma Chemical Co. (Buchs, Switzerland). IL-5 and IFN-
 
g
 
were obtained from Genzyme (Cambridge, MA). Unless stated
otherwise, all other reagents were obtained from Sigma Chemical Co.
 
iNOS Messenger RNA Expression in Nasal Polyp Tissues
 
RNA was isolated from fresh nasal polyp and inferior turbinate
tissues by using an RNA purification kit (Stratagene, Heidelberg,
Germany). The inferior turbinate tissues were obtained from two
individuals undergoing nasal surgery for deviation of the septum
and used as noninflamed control tissues. First strand cDNA syn-
thesis and PCR amplification was conducted as described (2, 9,
13, 25). Primers used for PCR amplification were oligonucleo-
tides recognizing sequences in iNOS (Clontech, Palo Alto, CA).
 
NO Production in Eosinophilic Inflammation
(Nasal Polyposis)
 
NO was measured in the nasal cavity of 20 patients with nasal
polyps and 20 normal control individuals. Both groups were age
and sex matched. Analysis was performed with a chemilumines-
cence analyzer (Eco Physics, Dürnten, Switzerland), which mea-
sures emitted light caused by the reaction NO 
 
1
 
 O
 
3
 
 
 
5
 
 NO
 
2
 
 
 
1
 
O
 
2
 
. One nasal olive was closed using an occlusive nasal olive from
a rhinomanometer (Homoth, Hamburg, Germany), and con-
nected to a syringe that had access to the nasal vestibulum. The
contralateral nostril was open. Subjects were asked to keep the
mouth closed. Thus, breathing was carried out through the open
nostril only. This allowed analysis of the local NO concentration
with free flow of air from one nostril to the other via the na-
sopharynx. Using the syringe, 20 ml of nasal air was aspirated
over a time period of 15 s. The aspirated air was injected into the
analyzer. NO concentrations were recorded by an on-line micro-
computer and given in parts per million. The analyzer was cali-
brated before each experiment using certified NO mixtures. NO
concentrations in the room were 
 
,
 
5 parts per billion.
 
Eosinophil Purification
 
Eosinophils were purified as previously described (7–9, 13, 25,
26). The resulting cell populations contained 99% eosinophils as
controlled by staining with Diff-Quik (Baxter, Düdingen, Swit-
zerland) and light microscopy.
 
Coculture of Fas Receptor–activated Eosinophils with
U937 Cells
 
The human monocyte-like cell line U937 was received from
American Type Culture Collection (Rockville, MD). U937 cells
were stimulated with 10 ng/ml LPS and 100 U/ml IFN-
 
g
 
 for 24 h
before coculture to induce iNOS expression. Freshly purified
eosinophils were incubated with 1 
 
m
 
g/ml anti-Fas mAb (IgM) for
1 h before coculture. Pretreated U937 cells and eosinophils were
cocultured at a 1:1 ratio for 24 h at 37
 
8
 
C in 5% CO
 
2
 
 and 95% air
in a humidified atmosphere. In additional experiments, the NOS
inhibitor NMMA (1 mM) was included at the start of U937 stim-
ulation. Furthermore, to block possible mediators, an inhibitor of
soluble guanylyl cyclase (sGC), LY 83583 (10 
 
m
 
M; reference 27),
and a neutralizing anti–GM-CSF mAb (20 
 
m
 
g/ml) were added to
the coculture. To determine eosinophil apoptosis in this system,
cells were morphologically examined. To this end, cytospin prep-
arations were made, stained with Diff-Quik, and photographed
under a Zeiss Axioscope microscope at 1,000 magnifications.
 
Determination of Cell Death
 
Eosinophils (10
 
6
 
/ml) were cultured in the presence or absence
of anti-Fas mAb or ceramides in the indicated conditions and for
the indicated times. Cell death of eosinophils was assessed by uptake
of 1 mM ethidium bromide and flow cytometric analysis (EPICS
XL; Coulter, Hialeah, FL) as previously described (7–9, 13).
 
Determination of Apoptosis
 
Determination of DNA Fragmentation.
 
Oligonucleosomal DNA
fragmentation, a characteristic feature of cells undergoing apopto-
sis, was assessed by flow cytometry as previously described (13).
 
Analysis of Phosphatidylserine Redistribution.
 
Phosphatidylserine
(PS) is normally confined to the inner plasma membrane leaflet.
In contrast, PS appears on the external leaflet in apoptotic cells.
Annexin V is a PS-binding protein and can be used to detect apo-
ptotic cells (28). The appearance of PS on the eosinophil cell sur-
face in response to the various indicated culture conditions was
assessed by flow cytometry (EPICS XL) using a commercial apo-
ptosis detection kit according to the manufacturer’s instructions
(R&D Sys., Inc.). 
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Determination of Acidic Sphingomyelinase Activity
 
Purified eosinophils were cultured in the presence or absence
of anti-Fas mAb in the indicated conditions and for the indicated
times. The ICE inhibitor II Ac-YVAD-cmk (1 
 
m
 
M) was added 2 h
before anti-Fas mAb stimulation. Sphingomyelinase (SMase) ac-
tivity in eosinophils was determined with an in vitro assay as pre-
viously described (29).
 
Determination of JNK Activation
 
Eosinophils were cultured in the presence or absence of C
 
2
 
-cer-
amide (C
 
2
 
) in the indicated conditions for 60 min. JNK activation
was measured as previously described (30).
 
Detection of Total Intracellular Proteolytic Activity
 
Fluorescamine Assay.
 
Protein fragmentation occuring during
Fas receptor–mediated apoptosis in eosinophils was first deter-
mined by the fluorescamine assay as previously described (31). In
brief, purified eosinophils were cultured in the presence or ab-
sence of anti-Fas mAb in the indicated conditions and for the in-
dicated times. Cells (10
 
6
 
) were washed twice with 1 ml homoge-
nization buffer (10 mM Hepes, 1 mM EGTA, pH 7.4, and 10 mM
PMSF), and then resuspended in 100 
 
m
 
l of this buffer. Cells were
lysed by sonication. 500 
 
m
 
l of fluorescamine solution (0.3 mg/ml
in acetone) were added to a quartz cuvette (Hellma, Basel, Swit-
zerland) containing 1 ml of a 1:100 dilution of cell lysates in ho-
mogenization buffer. Fluorescence was measured at excitation and
emission wavelengths of 390 nm and 480 nm, respectively, using
a FluoroMax spectrophotometer (Spex Industries Inc., Edison,
NJ). Intracellular proteolytic activity was determined as fluores-
cence intensity (cps)/
 
m
 
g protein cell lysate added to the cuvette.
Protein concentrations in the cell lysates were measured by a
Bradford protein assay (BioRad Labs., München, Germany).
 
Zymogram Gels.
 
To further confirm the data obtained using
the fluorescamine assay, we used Zymogram gels (Novex, San
Diego, CA). These 0.1% gelatin-containing and standardized 10%
SDS-polyacrylamide gels can be used to detect a wide variety of
proteases that can use gelatin as a substrate (32). After cell culture,
eosinophils (5 
 
3
 
 10
 
5
 
) were washed with cold PBS, resuspended
in 50 
 
m
 
l of sample buffer (0.06 M Tris-HCl, pH 6.8, 2% SDS,
0.0025% bromophenol blue, and 10% glycerol), and lysed by
sonication. Electrophoresis was conducted under standard condi-
tions according to the manufacturer’s instructions. Gels were in-
cubated in renaturing buffer (0.25% Triton X-100) for 30 min,
and then briefly washed with developing buffer (5 mM Tris-HCl,
pH 7.6, 20 mM NaCl, 0.5 mM CaCl
 
2
 
, and 0.002% Brij 35). The
gels were stained in 0.5% Coomassie Blue R 250, and partially
destained in destaining solution (10% CH
 
3
 
COOH, and 40%
CH
 
3
 
OH) to make digested gelatin spots visible.
 
Immunoblotting
 
We measured expression and/or degradation of lamin B
 
1
 
 in
eosinophils that had been cultured in the presence or absence of
anti-Fas mAb in the indicated conditions and for the indicated
times. Eosinophils (10
 
6
 
) were washed, resuspended in Lämmli
buffer, and lysed by sonication. Equal sample volumes of whole
cell lysates were applied to an 8% SDS polyacrylamide gel, and
separated proteins were electrotransferred onto a nitrocellulose
filter (Hybond–enhanced chemiluminescence [ECL]; Amersham
Intl., Buckinghamshire, UK). The blots were blocked at room
temperature for 1 h in blocking solution (10 mM Tris-HCl, pH
7.5, 100 mM NaCl, 0.1% Tween 20, and 5% BSA). Filters were
incubated in 1% BSA blocking solution containing 0.5 
 
m
 
g/ml
anti–lamin B
 
1
 
 mAb at room temperature for 1–2 h, followed by
incubation with horseradish peroxidase (HRP)-conjugated anti–
murine IgG
 
1
 
 mAb (1:2,000; Amersham Intl.). Blots were devel-
oped by an ECL technique (ECL kit; Amersham Intl.) according
to the manufacturer’s instructions.
 
Results
 
Increased NO Production in Nasal Polyp Tissues.
 
We have
previously reported that eosinophils in nasal polyp tissues
often have a decreased susceptibility to undergo apoptosis
after Fas receptor activation (13). Recently published work
suggests that NO may protect liver cells from TNF recep-
tor–mediated apoptosis (23). To verify a potential role of
NO for Fas receptor resistance in eosinophils, we measured
NO concentrations in the nasal cavity in 20 healthy sub-
jects and 20 patients with nasal polyps. As shown in Fig. 1
 
A
 
, NO concentrations were increased by fourfold in pa-
tients with nasal polyps, suggesting increased production of
NO in this model of eosinophilic inflammation.
Increased NO production is often achieved by activation
of the iNOS gene (22). Consequently, we investigated the
pattern of iNOS gene expression by reverse transcriptase
PCR in nasal polyp tissues. The results are shown in Fig. 1 
 
B.
 
Nasal polyp, but not control nasal tissues, expressed detect-
able iNOS messenger RNA (mRNA), as indicated by the
presence of a PCR product with the expected size of 257 bp.
iNOS specificity of this PCR product was demonstrated by
hybridization to an iNOS-specific probe. 
 
b
 
-actin–specific
amplification products were of similar intensity between all
samples, suggesting equality of the RNA populations. Thus,
it is likely that the expression of iNOS in nasal polyp tissues
Figure 1. Role of NO in
eosinophilic inflammation. (A)
Increased NO concentrations in
the nasal cavity of patients with
nasal polyps compared to normal
control individuals. Measure-
ments were performed with a
chemiluminescence analyzer as
described in Materials and Meth-
ods. Values are means 6 SEM.
This figure includes results from
20 different individuals in each
group (*, P , 0.001). (B) iNOS
mRNA is expressed in nasal
polyp tissues. In contrast, under
the same experimental condi-
tions, control nasal tissues ex-
pressed little or no iNOS
mRNA. RNA was isolated, and
first-strand synthesis was per-
formed. Human iNOS cDNA
was amplified by PCR using spe-
cific iNOS primers. The PCR products were electrophoresed on a 1%
agarose gel, transferred onto a nitrocellulose filter, and hybridized with a
random-primed fluorescein-12-dUTP–labeled iNOS probe. As a control,
human b-actin cDNA was amplified and PCR products were stained by
ethidium bromide in an agarose gel. Data from four different patients
with nasal polyps and two control individuals are presented. 
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accounts for the increased NO production measured in the
nasal cavities of these patients.
 
NO Inhibits Fas Receptor–induced Apoptosis of Eosino-
phils.
 
To more directly determine a possible role of NO
for the reduction of eosinophil sensitivity to Fas receptor–
mediated apoptosis, we cocultured stimulated monocytic-
like U937 cells with anti–Fas receptor–activated freshly pu-
rified eosinophils. U937 cells were stimulated with LPS and
IFN-
 
g
 
 to induce iNOS expression and NO production. As
shown in Fig. 2, eosinophils undergo normal Fas receptor–
mediated apoptosis under conditions where U937 cells
were not stimulated. In contrast, LPS– and IFN-
 
g
 
–stimu-
lated U937 cells prevented eosinophil apoptosis in this cocul-
ture system. This suggests that activated U937 cells produce
a factor that counterregulates Fas receptor–mediated death.
Moreover, addition of 1 mM NMMA (NOS inhibitor) or
10 
 
m
 
M LY 83583 (sGC inhibitor; NO signals via sGC; ref-
erence 27) abolished the effect of stimulated U937 cells on
Fas receptor–mediated eosinophil apoptosis (Fig. 2). In ad-
dition, since activated U937 cells may also produce eosino-
phil survival factors such as GM-CSF, we also used a neu-
tralizing anti–human GM-CSF mAb in this system, and
observed no effect on Fas receptor–mediated eosinophil apo-
ptosis (not presented). These data suggest that NO, but not
GM-CSF, is involved in U937-mediated Fas receptor resis-
tance of eosinophils.
To complement these studies and to establish a func-
tional approach without the need of a coculture system, we
generated NO in pure eosinophil cultures either by endog-
enous catalase from azide or hydroxylamine or by hydroly-
sis from SNAP (33, 34). As shown in Fig. 3 
 
A
 
, cell viability
of purified eosinophils from individuals with normal or
slightly increased eosinophil numbers averaged 63 
 
6
 
 2% af-
ter 24 h of in vitro culture. Anti-Fas mAb treatment accel-
erated eosinophil death by twofold (31 
 
6
 
 3%). Azide, in
the range of 0.02 to 1.2 mM, hydroxylamine, in the range
of 0.3 to 1.2 mM, and SNAP, in the range of 0.001 to 1 mM,
significantly inhibited Fas receptor–mediated eosinophil
death. At optimal concentrations, the rescue effect was 95%
for azide (1.2 mM), 89% for hydroxylamine (1.2 mM), and
100% for SNAP (1 mM) (Fig. 3 
 
B
 
). Similar to the coculture
system, LY 83583 abrogated the protective effect of 1 mM
SNAP on anti-Fas mAb-induced eosinophil death. More-
over, the specific eosinophil survival factor IL-5 (3, 4) had
only little rescue effects (17%) in this system (Fig. 3 
 
B
 
). In
addition, similar to IL-5, IFN-
 
g
 
, IL-3, and GM-CSF were
unable to significantly protect eosinophils from Fas recep-
tor–mediated death (not presented). Furthermore, and in
contrast to the strong rescue effect of NO on Fas receptor–
activated cells, it is important to note that all NO donors
only slightly inhibited spontaneous eosinophil death (16%
for azide, 18% for hydroxylamine, and 5% for SNAP).
Using a DNA fragmentation assay and flow cytometric
analysis of surface PS expression, we demonstrated that the
anti-Fas mAb triggered apoptotic cell death. This apoptotic
cell death was inhibited by NO. We found 35 
 
6
 
 2% DNA
fragmentation in nontreated purified eosinophils after 16 h
of in vitro culture (Fig. 4 
 
A a
 
). Anti-Fas mAb treatment of
eosinophils increased the levels of DNA fragmentation to
64 
 
6
 
 4% DNA (Fig. 4 
 
A b
 
). In this system, SNAP inhibited
Fas receptor–mediated apoptosis in a dose-dependent man-
ner (Fig. 4 
 
A
 
, 
 
c, and d and right). Similar results were ob-
tained using azide and hydroxylamine as NO donors (not
presented). Moreover, anti-Fas mAb-induced externaliza-
tion of PS, an early marker of apoptosis (28), was inhibited
in the presence of 1 mM SNAP, further suggesting that
NO inhibits typical apoptotic processes induced by Fas re-
ceptor activation in human eosinophils (Fig. 4 B).
NO Causes Reduced Fas Receptor Sensitivity via sGC in
Eosinophils. sGC is generally accepted as being the main
molecular target of NO leading to the production of
cGMP. The subsequent regulation of cGMP-dependent
protein kinases, nucleotide phosphodiesterases, and ion chan-
nels mediates most of the physiological NO functions (35).
Therefore, we mimicked intracellular cGMP increases after
sGC activation by adding cell membrane-permeable dibu-
tyryl (db)-cGMP to the in vitro cultures. Similarly to SNAP,
azide, or hydroxylamine, db-cGMP reduced anti-Fas mAb-
induced death in purified eosinophils in a dose-dependent
manner (Fig. 5 A). The inhibition of cell death was 100% at
Figure 2. Activated U937 cells prevent Fas receptor–mediated apopto-
sis in eosinophils. Purified eosinophils were stimulated with anti-Fas
mAb, and cocultured with U937 cells for 24 h. LPS– and IFN-g–stimu-
lated U937 cells produce a factor that prevents eosinophils apoptosis. In
contrast, unstimulated U937 cells or cocultures incubated with the NOS
inhibitor NMMA or the sGC inhibitor LY 83583 did not prevent eosino-
phil apoptosis (original magnification: 1,000). Neutralizing anti–GM-CSF
mAb did not counteract the effects of the factor that prevents eosinophil
apoptosis in this system (not presented).419 Hebestreit et al.
50 mM db-cGMP. In contrast, DAG, an important second
messenger molecule in other signaling systems, had no effect
on Fas receptor–mediated eosinophil death (not presented),
indicating specificity of the observed db-cGMP effects.
The generation of cGMP subsequently inhibits a cGMP-
regulated cyclic nucleotide phosphodiesterase (35) and, con-
sequently, increases intracellular cAMP. Therefore, mem-
brane-permeable db-cAMP was added to our system to
mimic increases in cAMP levels. Similarly to db-cGMP, db-
cAMP was an effective blocker of Fas receptor–mediated
eosinophil death (Fig. 5 A). In fact, the db-cAMP rescue
effect was, at concentrations between 1 and 50 mM, even
more potent than db-cGMP.
cGMP and cAMP are both targets of regulatory phos-
phodiesterases that cleave these molecules to 59-GMP and
59-AMP, respectively. To confirm the roles for cGMP and
cAMP in the reduction of eosinophil sensitivity to Fas re-
ceptor–mediated apoptosis, we next inhibited phosphodi-
esterases by using IBMX to increase intracellular cGMP
and cAMP levels. Previously published work has demon-
strated that inhibition of phosphodiesterase activity enhances
NO effects (36). Therefore, we performed experiments us-
ing suboptimal concentrations of the NO donor SNAP to
investigate whether IBMX is able to increase SNAP-medi-
ated protection from cell death. Inhibition of phosphodi-
esterase activity by IBMX and suboptimal concentrations of
SNAP blocked Fas receptor–mediated death almost com-
pletely, whereas IBMX had no significant effect when opti-
mal concentrations of SNAP were used (Fig. 5 B). We also
performed DNA fragmentation assays and observed similar
results (not presented). Together, these data suggest that
NO exerts its potent inhibitory effect on Fas receptor–
mediated apoptosis through activation of sGC and conse-
quent enhancement of intracellular cGMP and cAMP levels.
NO Inhibits Fas Receptor Signaling Events Distal to Acidic
SMase Activition in Eosinophils. In preliminary experiments,
we excluded the possibility of Fas receptor downregulation
as a mechanism to reduce eosinophil sensitivity to Fas re-
ceptor–mediated apoptosis by NO (not presented). Rather,
this implied that the reduced sensitivity of NO-treated
eosinophils to Fas receptor–mediated apoptosis reflected a
functional defect to transduce signals via this receptor. Pre-
viously published work suggested that acidic SMase-gener-
ated ceramide is involved in the Fas receptor signaling
pathway leading to apoptosis (29, 37, 38). Therefore, the
effect of anti-Fas mAb treatment on SMase activity was
studied in the absence and presence of optimal concentra-
tions of SNAP. Enzyme activity was determined by degra-
dation of radioactively labeled sphingomyelin (SM) in an in
vitro assay. As shown in Fig. 6 A, anti-Fas mAb treatment
was followed by induction of SMase activity in both
SNAP-untreated and -treated eosinophils, indicating that
NO may act distally from SM breakdown. In contrast, the
ICE inhibitor II Ac-YVAD-cmk abrogated Fas receptor–
mediated activation of SMase (Fig. 6 A), suggesting that
SM breakdown is distal to early ICE protease activation in
the Fas receptor signaling pathway.
We next investigated whether SMase-generated ceramide
could induce apoptosis in eosinophils as it has been re-
ported in other systems (29, 37, 38). Indeed, 10–50 mM
C2- or C6-ceramide induced, in a dose-dependent manner,
eosinophil death (Fig. 6 B). In contrast, the biologically in-
active structural analogue of C2-ceramide, C2-dihydrocer-
amide, had no effect on cell death in the same concentra-
tion range. Higher ceramide concentrations were found to
damage the cell membrane. To determine whether NO
can counterregulate ceramide-induced apoptosis, untreated
and C2-ceramide–treated eosinophils were incubated in the
absence and presence of optimal concentrations of SNAP,
db-cGMP, and db-cAMP. SNAP, db-cGMP, and db-
cAMP inhibited C2-ceramide–induced cell death (Fig. 6 C)
and DNA fragmentation (not presented). These data sug-
gest that NO, as well as its second messengers, counterreg-
ulate Fas receptor signaling distal to ceramide generation.
Figure 3. Fas receptor–mediated
death is prevented by NO, but not
by IL-5 in freshly purified eosino-
phils. (A) Three different NO do-
nors (azide and hydroxylamine re-
lease NO due to endogenous
catalase activity; SNAP spontane-
ously releases NO) inhibited, in a
dose-dependent manner, Fas recep-
tor–mediated eosinophil death. Hori-
zontal lines, cell viability of untreated
eosinophils. Eosinophils were cul-
tured for 24 h in the presence of
anti-Fas mAb and NO donors at the
indicated concentrations. Cell viabil-
ity was assessed by uptake of 1 mM
ethidium bromide and flow cyto-
metric analysis. Values are means 6
SEM of three independent experi-
ments. (B) In contrast to NO, opti-
mal concentration of IL-5 (50 ng/
ml) did not inhibit Fas receptor–mediated eosinophil death. LY 83583 was used to demonstrate the specificity of NO-mediated effects. Experiments were
performed as described in A. The percentage of inhibition of Fas receptor–mediated eosinophil death was calculated. Values are means 6 SEM of three in-
dependent experiments.420 NO-mediated Fas Receptor Resistance in Eosinophils
NO Inhibits Fas Receptor–induced JNK Activation. Recently,
it has been demonstrated that both Fas receptor activation
as well as the presence of C2-ceramide results in activation
of an alternative mitogen-activated protein (MAP) kinase
pathway  leading to JNK activation followed by apoptosis in
human T and B cells (30, 39). Activated JNK phosphory-
lates c-Jun in many systems (40–42). Therefore, phosphor-
ylation of GST-c-Jun (1–79) was used to measure JNK ac-
tivity by an immune complex kinase assay. As shown in
Fig. 6 D, C2-ceramide stimulation for 60 min induced
phosphorylation of c-Jun. In contrast, these increases were
abolished by the second messengers of NO cGMP and
cAMP. These data suggest that NO interrupts the Fas recep-
tor signaling pathway at the level of, or proximal to, JNK
activation.
NO Inhibits Fas Receptor–induced Proteolytic Activity in
Eosinophils. Since proteases are believed to be the central
components of the cell death machinery (43), we analyzed
proteolytic activity in Fas receptor–activated eosinophils
and its modulation by NO. Total protease activation was first
assessed using a fluorescence assay to measure the amounts
of degraded proteins by conjugating terminal amino groups
to the fluorochrome Fluram. Anti-Fas mAb stimulation of
eosinophils for 16 h resulted in an increase in specific fluo-
rescence intensity in the Fluram assay by a factor of 2.3,
indicating increased proteolytic activity. This increase was
not detected in the presence of optimal SNAP concentra-
tions (Fig. 7 A). Intracellular proteolytic activity was also
analyzed by separating and incubating cell lysates on a Zymo-
gram gel that contained 0.1% gelatin. Again, Fas receptor–
activated eosinophils demonstrated elevated proteolytic ac-
tivity compared to unstimulated cells (Fig. 7 B). Increased
proteolytic activity after Fas receptor activation involved
proteases with molecular masses of 49, 58, 84, and between
90 and 95 kD beginning 7 h after stimulation. In contrast,
additional treatment of eosinophils with 50 mM db-cGMP
resulted in reduced proteolytic acitivity in these cells. More-
over, the pattern of protease activation did not differ be-
tween spontaneously and anti-Fas mAb-mediated dying cells.
These data suggest that NO reduces activation of proteases
within the Fas receptor signaling pathway, and thereby pre-
vents Fas receptor–mediated apoptosis in eosinophils.
Previous studies have identified important targets of pro-
teases that execute cell death. One of these targets is a nu-
clear 74-kD protein, lamin B1. In contrast to the slow turn-
over of lamins in nonapoptotic cells (t1/2 . 24 h), apoptotic
cells are characterized by a rapid decrease in levels of intact
lamins (44). Lamin cleavage seems to be required for pack-
aging of the condensed chromatin into apoptotic bodies (45).
Therefore, we characterized cleavage of lamin B1 in Fas re-
ceptor–activated eosinophils in the presence or absence of
Figure 4. NO prevents Fas receptor–mediated apoptosis in freshly pu-
rified eosinophils. (A) SNAP inhibited, in a dose-dependent manner, Fas
receptor–mediated DNA fragmentation. Eosinophils were cultured for
16 h. DNA fragmentation (black) was determined by DNA staining with
propidium iodide and flow cytometric analysis. (Left) a, untreated; b, anti-
Fas mAb; c, anti-Fas mAb plus 0.5 mM SNAP; d, anti-Fas mAb plus 1 mM
SNAP. (Right) Values are means 6 SEM of three independent experi-
ments. (B) SNAP inhibited Fas receptor–mediated redistribution of PS.
Eosinophils were cultured for the indicated times. FITC-conjugated an-
nexin V binding (black) was assessed by flow cytometric analysis. (Left,
measurements after 8 h) a, untreated; b, anti-Fas mAb; c, anti-Fas mAb
plus 0.5 mM SNAP; d, anti-Fas mAb plus 1 mM SNAP. (Right) Values
are means 6 SEM of three independent experiments.
Figure 5. Fas receptor–mediated death is prevented by NO-induced
second messengers in freshly purified eosinophils. (A) cGMP and cAMP
inhibited, in a dose-dependent manner, Fas receptor–mediated death. In
contrast, DAG had no effect in this system (not presented). The dashed
line represents cell viability of untreated eosinophils. Eosinophils were cul-
tured for 24 h. Cell viability was assessed by uptake of 1 mM ethidium
bromide and flow cytometric analysis. Values are means 6 SEM of three
independent experiments. (B) Inhibition of phosphodiesterase activity by
IBMX enhanced low-dose NO effects. 0.5 mM, but not 0.1 mM, SNAP
inhibited Fas receptor–mediated eosinophil death. However, 0.1 mM
SNAP could completely block death when IBMX was added. Experi-
ments and analysis were performed as described in A. Values are means 6
SEM of three independent experiments.421 Hebestreit et al.
SNAP by Western blotting. As shown in Fig. 7 C, com-
plete cleavage of lamin B1 occurred within 4 h after anti-
Fas mAb treatment. In contrast, optimal concentrations of
SNAP completely inhibited Fas receptor–mediated cleav-
age of lamin B1, whereas a suboptimal SNAP concentration
was only partially protective. In addition, a second protein
with a molecular mass of z70 kD reacted with the anti-
body, probably representing an early degradation product
of lamin B1. These data suggest that NO blocks the pro-
teolytic action of proteases on specific target proteins that
are important for the apoptotic process, such as lamin B1.
Discussion
Allergic diseases of the respiratory tract are associated with
a marked eosinophilic inflammation (46) and enhanced cy-
tokine production (47). Some of these cytokines inhibit
eosinophil apoptosis and may, therefore, contribute to tis-
sue eosinophil accumulation (1, 2). In addition to these ef-
fects, there is evidence to suggest upregulation of iNOS in
eosinophilic inflammation airways (17). Consequently, mea-
surements of NO in exhaled air have demonstrated ele-
vated levels in asthma and seasonal allergic rhinitis patients
(14, 15, 22). In agreement with these studies, we measured
increased NO levels within the nasal cavity of patients with
nasal polyps. We also provided evidence for increased
iNOS mRNA expression in polyp tissues. Together with the
previously published work (14, 15, 22), these data suggest that
Figure 6. NO inhibits Fas receptor signaling events at the level of, or
proximal to, JNK, but distal to acidic SMase activation in freshly purified
eosinophils. (A) The ICE inhibitor Ac-YVAD-cmk (1 mM), but not
SNAP (1 mM), blocked acidic SMase activation. Eosinophils were stimu-
lated, as indicated, for 20 min. SMase activity was assessed in cell lysates
by a radioactive in vitro assay using 14C-SM as a substrate. SMase activity
is presented as percent degraded substrate calculated from densitometry
measurements after autoradiography. Values are means 6 SEM of three
independent experiments. (B) The ceramide analogues C2- and C6-cer-
amide induced, in a dose-dependent manner, eosinophil death. In con-
trast, biologically inactive C2-dihydroceramide (DH-C2) had no effect in
this system. Eosinophils were cultured for 24 h. Cell viability was assessed
by uptake of 1 mM ethidium bromide and flow cytometric analysis. Values
are means 6 SEM of three independent experiments. (C) SNAP (1 mM),
cGMP (50 mM), and cAMP (5 mM) inhibited C2-ceramide–mediated
eosinophil death. Experiments and analysis were performed as described
in B. Values are means 6 SEM of three independent experiments. (D)
cGMP (50 mM) and cAMP (5 mM) abrogated anti-Fas mAb- or ceramide-
mediated phosphorylation of c-Jun. Eosinophils were stimulated for 60
min. The cell lysates were immunoprecipitated with an anti-JNK Ab, and
phosphorylation of GST-c-Jun (1–79) was observed by in vitro kinase assay.
Figure 7. NO and NO-mediated second messengers inhibit activation
of intracellular proteases in freshly purified eosinophils. (A) SNAP (1 mM)
inhibited anti–Fas receptor–mediated activation of intracellular proteases.
Intracellular proteolytic activity was assessed by a fluorescence assay; levels
of terminal amino groups were measured by binding of Fluram and fluo-
rescence spectrometry. Eosinophils were cultured for 16 h. Values are
means 6 SEM of three independent experiments. (B) cGMP (50 mM)
inhibited anti–Fas receptor–mediated activation of intracellular proteases.
A time course of intracellular proteolytic activity was assessed by Zymo-
gram electrophoresis. Spontaneous and anti–Fas receptor–mediated eosin-
ophil apoptosis was associated with the activation of proteases with mo-
lecular masses of 49, 58, 84, and between 90 and 95 kD. (Right) The
positions of molecular size standards. (C) SNAP inhibited, in a dose-
dependent manner, Fas receptor–mediated proteolysis of lamin B1. Eosin-
ophils were cultured for 4 h. Immunoblot analysis of cell lysates was per-
formed with anti–lamin B1 mAb. The full-length lamin B1 is indicated
(arrow). (Right) The positions of molecular size standards.422 NO-mediated Fas Receptor Resistance in Eosinophils
increased NO production may represent a general feature of
eosinophilic inflammation.
Fas receptors are broadly expressed on many different cell
types. Activation of the Fas receptors leads to induction of
apoptosis in many, but not all systems (48). For example,
hematopoietic and nonhematopoietic tumor cells resistant
to Fas receptor–mediated apoptosis have been found, al-
though they express the receptor on the cell surface (49,
50). Therefore, the mechanisms of Fas receptor resistance
have generated great interest. The results presented in this
study suggest a novel NO-mediated mechanism causing non-
functional Fas receptors by disruption of the death signaling
pathway in human eosinophils.
Extensive analysis of the signaling pathways associated
with Fas receptor–mediated apoptosis has revealed that
oligomerization of the receptor induces conformational
changes of the intracellular domains leading to binding of
cytoplasmic proteins and formation of the death-inducing
signaling complex (DISC; 51). One of the DISC proteins is
an ICE-like protease (24, 52). Thus, perhaps there is a di-
rect physical connection between initialization of the death
signal at the cell membrane and the death machinery (48).
However, other cell signaling events involving tyrosine phos-
phorylation (53), SMase-ceramide (29, 37, 38), and Ras/Raf/
MAP kinase pathways (39, 40) have also been reported to
be involved in cell death. The contribution of all of these
pathways to the induction of apoptosis as well as possible
interactions between different pathways have not yet been
clearly elucidated.
Ceramide, generated by activated SMase, triggers apo-
ptosis in response to Fas receptor activation (29, 37, 38)
and many other death stimuli (54). Thus, ceramide produc-
tion appears to be a pleiotropic activator of apoptosis.
Therefore, we first analyzed activation of SMase after Fas
receptor activation in the presence and absence of NO or
second messengers of NO. This strategy allowed us to de-
termine whether the possible disruption of the Fas receptor
signaling pathway by NO occurs proximal or distal to
SMase activation. We observed a Fas receptor–mediated
activation of SMase in both NO-untreated and -treated
eosinophils, suggesting that NO may block the death signal
distal to SMase. The possibility to inhibit Fas receptor–ini-
tiated signaling events downstream of SMase activation has
been previously demonstrated in cells overexpressing Abl
tyrosine kinases (55). In contrast to the effects observed
with NO donors, activation of SMase was abrogated when
the tetrapeptide YVAD was used to block activation of the
ICE protease. In agreement with a previously published
work (56), these data demonstrate that activation of ICE
proteases is required for SMase activation. Moreover, these
data indicate that NO did not disrupt DISC formation in
Fas receptor–activated eosinophils.
There has been some progress in the identification of cer-
amide targets. The first reported target for its activity was a
serine/threonine protein kinase, termed ceramide-activated
protein kinase, that was only recently identified (57). The
target of this kinase appears to be the protooncogene Raf
(57). Moreover, Fas receptor activation and ceramide in-
duce activation of another, alternative MAP kinase path-
way resulting in JNK stimulation. JNK activation has been
shown to be critical for induction of apoptosis in many sys-
tems (30, 39). To examine the possibility of a functional
JNK inactivation by NO, we monitored kinase activity af-
ter anti-Fas mAb or ceramide treatment of eosinophils in
the presence and absence of NO or second messengers of
NO. The results suggest that JNK activation is also neces-
sary for Fas receptor–mediated apoptosis in eosinophils.
Moreover, since second messengers of NO prevent c-Jun
phosphorylation, NO may act at the level of, or proximal
to, JNK activation to prevent death.
It is now clear that proteases play a key role in apoptosis
(43, 48). This study provides evidence that NO prevents
Fas receptor–mediated proteolysis. However, the observa-
tion that it is possible to block activation of SMase by using
an inhibitor of ICE suggests that there is some protease ac-
tivation even in the presence of NO. It has recently been
demonstrated that activation of a protease can lead to fur-
ther activation of other proteases within the apoptotic pro-
cess (58), generating a protease cascade (43, 48). We hy-
pothesize at this point that the generation of ceramide and
subsequent JNK activation may represent a signaling event
responsible for amplification of the proteolytic cascade.
Therefore, disruption of ceramide-induced signals prevents
further proteolysis. This idea is further supported by very
recent reports demonstrating that the central ICE-like pro-
tease CPP32 (Yama/Apopain) is not only a target of ICE
(58) but, at least in a later phase of the apoptotic death pro-
cess, also of MAP kinase and JNK signaling pathways (59).
Thus, it is possible that, even in the presence of NO, activa-
tion of eosinophils via the Fas receptor leads to an immediate
but limited activation of proteases able to degrade only a lim-
ited number of substrates. These can then be replaced with-
out any damage to the cell. In contrast, in the absence of NO,
ceramide-mediated amplification of the proteolytic cascade
takes place and the apoptotic process initialized via the Fas
receptor proceeds, causing irreversible damage to the cell.
In summary, the data reported here indicate that NO, a
secretory product released in increased amounts within
chronic eosinophilic inflammatory responses such as bron-
chial asthma and other chronic-allergic disorders, disrupts
Fas receptor–mediated apoptosis in eosinophils. Therefore,
we have identified a mechanism of Fas receptor resistance
that might contribute to the eosinophilia associated with
these diseases. In this context, it is tempting to speculate
that glucocorticoids, which are known to suppress NO con-
centration in asthmatic patients (15), decrease eosinophil
numbers, besides other possible mechanisms, by sensitiza-
tion of the Fas receptor. Moreover, we have localized the
disruption of the Fas signaling pathway by NO at the level
of, or proximal to, JNK, but distal to SMase activation. We
also provide evidence that the ceramide-induced apoptotic
response may serve as an amplification step within the pro-
teolytic cascade of the apoptotic process that, on the other
hand, can be counterregulated by additional signals.423 Hebestreit et al.
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